Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Olympus Corporation (7733.T)
Tokyo, JP
Olympus Corporation, a global enterprise headquartered in Tokyo, Japan, manufactures and distributes high-precision machinery and instrumentation worldwide. The company, originally established in 1919 as Olympus Optical Co., Ltd., adopted its current name in October 2003. Its extensive operations are structured into four primary divisions: Endoscopic Solutions, Therapeutic Solutions, Scientific Solutions, and a segment designated as "Others." The Endoscopic Solutions division specializes in developing and providing gastrointestinal and surgical endoscopes, comprehensive endoscopy systems, and associated repair services. The Therapeutic Solutions segment focuses on products for urology, gynecology, and ear, nose, and throat (ENT) procedures, alongside endo-therapy devices, energy-based surgical tools, and disposable surgical instruments. Within Scientific Solutions, Olympus supplies biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing (NDT) equipment, and X-ray fluorescence (XRF) analyzers. The "Others" segment encompasses biomedical materials and orthopedic equipment. Beyond these core areas, the company also offers a broader array of medical devices, including surgical microscopes, endoscope reprocessing units, electrosurgical tools, and respiratory-endotherapy devices, complemented by system integration and ongoing maintenance services.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +19.83% | +18.30% | +20.26% | -0.35% | -11.63% | -9.27% | -8.48% | -18.79% | -9.95% | +77.07% | +659.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 9 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Devices: +11.2%+1.3% Q1'26: +8.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-40.5% Q1'26: -38.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+10.8% Q1'26: +10.2% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+14.6% ★ Q1'26: +18.1% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+12.4% ★ Q1'26: +22.7% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-2.8% ★ Q1'26: -2.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.12× Q1'26: 0.86× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 13 Rev. Ana. 11 EPS Ana. |
Mar 2027 5 Rev. Ana. 8 EPS Ana. |
Mar 2028 12 Rev. Ana. 12 EPS Ana. |
Mar 2029 6 Rev. Ana. 6 EPS Ana. |
Mar 2030 3 Rev. Ana. 2 EPS Ana. |
Mar 2031 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
764.67B
est: 764.42B (+0.0%)
|
804.58B
est: 815.91B (-1.4%)
|
740.56B
est: 746.08B (-0.7%)
|
786.50B
est: 786.43B (+0.0%)
|
793.86B
est: 794.78B (-0.1%)
|
755.23B
est: 793.94B (-4.9%)
|
730.54B
est: 723.80B (+0.9%)
|
750.12B
est: 863.58B (-13.1%)
|
881.92B
est: 881.40B (+0.1%)
|
925.75B
est: 966.05B (-4.2%)
|
997.33B
est: 997.94B (-0.1%)
|
996.77B
985.64B – 1.02T
-0.1% YoY
|
1.05T
1.04T – 1.07T
+5.6% YoY
|
1.10T
1.07T – 1.14T
+4.2% YoY
|
1.14T
1.14T – 1.15T
+4.0% YoY
|
1.17T
1.14T – 1.20T
+2.2% YoY
|
1.21T
1.19T – 1.24T
+3.8% YoY
|
| EBITDA |
142.35B
est: 170.37B (-16.4%)
|
154.24B
est: 181.85B (-15.2%)
|
135.08B
est: 166.29B (-18.8%)
|
137.20B
est: 175.28B (-21.7%)
|
130.84B
est: 177.14B (-26.1%)
|
169.91B
est: 176.95B (-4.0%)
|
164.77B
est: 161.32B (+2.1%)
|
213.97B
est: 192.48B (+11.2%)
|
243.21B
est: 196.45B (+23.8%)
|
215.28B
est: 245.82B (-12.4%)
|
252.49B
est: 253.93B (-0.6%)
|
253.64B
250.80B – 258.77B
-0.1% YoY
|
267.90B
265.23B – 271.69B
+5.6% YoY
|
279.25B
271.83B – 289.57B
+4.2% YoY
|
290.35B
289.05B – 291.65B
+4.0% YoY
|
296.70B
291.23B – 304.34B
+2.2% YoY
|
308.07B
302.39B – 316.01B
+3.8% YoY
|
| EBIT |
91.71B
est: 112.01B (-18.1%)
|
104.46B
est: 119.56B (-12.6%)
|
80.79B
est: 109.33B (-26.1%)
|
84.28B
est: 115.24B (-26.9%)
|
72.17B
est: 116.46B (-38.0%)
|
101.60B
est: 116.34B (-12.7%)
|
104.84B
est: 106.06B (-1.2%)
|
149.36B
est: 126.55B (+18.0%)
|
176.47B
est: 129.16B (+36.6%)
|
149.34B
est: 172.06B (-13.2%)
|
186.04B
est: 177.75B (+4.7%)
|
177.54B
175.55B – 181.13B
-0.1% YoY
|
187.52B
185.65B – 190.17B
+5.6% YoY
|
195.47B
190.27B – 202.69B
+4.2% YoY
|
203.24B
202.33B – 204.15B
+4.0% YoY
|
207.68B
203.85B – 213.03B
+2.2% YoY
|
215.64B
211.67B – 221.20B
+3.8% YoY
|
| Net Income |
-8.74B
est: 36.00B (-124.3%)
|
62.59B
est: 45.81B (+36.6%)
|
42.78B
est: 65.96B (-35.1%)
|
57.06B
est: 51.97B (+9.8%)
|
8.15B
est: 20.93B (-61.1%)
|
80.29B
est: 52.97B (+51.6%)
|
57.71B
est: 25.76B (+124.0%)
|
115.74B
est: 95.07B (+21.7%)
|
143.43B
est: 129.89B (+10.4%)
|
242.57B
est: 26.96B (+799.8%)
|
117.86B
est: 107.49B (+9.6%)
|
56.48B
48.55B – 89.45B
-47.5% YoY
|
100.69B
96.01B – 105.37B
+78.3% YoY
|
115.72B
101.15B – 156.61B
+14.9% YoY
|
126.14B
123.62B – 145.38B
+9.0% YoY
|
150.96B
147.34B – 156.01B
+19.7% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
165.63B
est: 340.69B (-51.4%)
|
348.60B
est: 363.64B (-4.1%)
|
366.78B
est: 332.52B (+10.3%)
|
307.33B
est: 350.50B (-12.3%)
|
313.53B
est: 354.22B (-11.5%)
|
251.36B
est: 353.85B (-29.0%)
|
299.95B
est: 322.59B (-7.0%)
|
241.33B
est: 384.89B (-37.3%)
|
309.36B
est: 392.83B (-21.2%)
|
351.23B
est: 355.44B (-1.2%)
|
376.18B
est: 367.18B (+2.5%)
|
366.75B
362.65B – 374.17B
-0.1% YoY
|
387.37B
383.51B – 392.85B
+5.6% YoY
|
403.79B
393.05B – 418.71B
+4.2% YoY
|
419.84B
417.96B – 421.72B
+4.0% YoY
|
429.01B
421.11B – 440.06B
+2.2% YoY
|
445.46B
437.25B – 456.94B
+3.8% YoY
|
| EPS |
-6.38
est: 31.40 (-120.3%)
|
45.73
est: 39.96 (+14.4%)
|
31.25
est: 57.53 (-45.7%)
|
41.71
est: 45.33 (-8.0%)
|
5.97
est: 18.26 (-67.3%)
|
61.18
est: 46.20 (+32.4%)
|
44.89
est: 22.47 (+99.8%)
|
90.22
est: 82.93 (+8.8%)
|
113.22
est: 113.53 (-0.3%)
|
199.91
est: 23.40 (+754.2%)
|
102.99
est: 93.32 (+10.4%)
|
50.37
42.35 – 78.02
-46.0% YoY
|
87.61
83.75 – 91.91
+73.9% YoY
|
106.69
88.23 – 136.61
+21.8% YoY
|
115.45
107.83 – 126.81
+8.2% YoY
|
131.68
128.52 – 136.09
+14.1% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert John White | Representative Executive Officer, President, Chief Executive Officer & Director | 1B | male |
| Stephen Kneebone | Corporate Officer & Chief Information Officer | 734M | — |
| Frank Drewalowski | Senior advisor to CEO | 522M | male |
| Syed Mukarram Naveed | Executive Officer & Chief Technology Officer | 462M | male |
| Yasuo Takeuchi | Representative Executive Officer, Executive Chairperson & ESG Officer | 379M | male |
| Gabriela Kaynor | Executive Officer & Chief Strategy Officer | 300M | female |
| Shkolnik Boris | Executive Officer & Chief Quality Officer | 274M | — |
| Neil Boyden Tanner | Executive Officer & Global General Counsel | 175M | male |
| John de Csepel | Executive Officer & Chief Medical Officer | 156M | male |
| Tetsuo Kobayashi | Executive Officer and Chief Manufacturing & Supply Officer | 125M | male |
| Tatsuya Izumi | Executive Officer & Chief Financial Officer | 123M | — |
| Takayuki Aoyagi | Vice President of Accounting | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7733.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
